Stock Update (NASDAQ:ENDP): Endo International plc – Ordinary Shares Announces Appointment of Blaise Coleman as Chief Financial Officer


Endo International plc – Ordinary Shares (NASDAQ: ENDP) announced that it has appointed Blaise Coleman as Executive Vice President and Chief Financial Officer, effective December 19, 2016. Mr. Coleman has been serving as Endo’s Interim Chief Financial Officer since November 22, 2016.

“After a thorough assessment and search process, Endo’s Board of Directors has concluded that Mr. Coleman is the strongest candidate for the position and I could not be more pleased. Blaise and I have built a strong working relationship over the past 12 months so I’m excited to officially have Blaise permanently join the Endo Executive Leadership Team,” said Paul Campanelli, President and Chief Executive Officer of Endo. “In addition to his years of Company experience, Blaise brings significant industry experience, a successful track record of delivering value and strong leadership skills to his role. We look forward to his continued contributions to our Company.”

Mr. Coleman joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis, and was then promoted to Senior Vice President, Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, most recently as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance.

Prior to that, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden. Mr. Coleman joined AstraZeneca in 2007 as Senior Director Commercial Finance for the US Cardiovascular Business. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in both the Licenses & Acquisitions and Commercial Finance organizations.

Mr. Coleman’s move to Centocor in early 2003 followed 7 years’ experience with the global public accounting firm, PricewaterhouseCoopers LLP. Mr. Coleman is a Certified Public Accountant; he holds a Bachelor of Science degree in accounting from Widener University and an M.B.A. from the Fuqua School of Business at Duke University.

“I would like to thank Paul and the Board for their continued confidence and I am excited to serve Endo, our employees, shareholders and customers in my new role,” said Mr. Coleman. “I look forward to supporting the team as we continue our efforts to re-focus and grow the business and prepare to execute on our new corporate strategy in 2017.” (Original Source)

Shares of Endo are currently rising 0.37% to $16.09, or up $0.06 in pre-market trading Tuesday. ENDP has a 1-year high of $63.63 and a 1-year low of $12.56. The stock’s 50-day moving average is $16.39 and its 200-day moving average is $18.58.

On the ratings front, Endo has been the subject of a number of recent research reports. In a report issued on December 9, JMP analyst Donald Ellis reiterated a Buy rating on ENDP, with a price target of $34, which represents a potential upside of 112% from where the stock is currently trading. Separately, on December 8, Oppenheimer’s Derek Archila reiterated a Hold rating on the stock.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Donald Ellis and Derek Archila have a yearly average return of 12.1% and a loss of -1.1% respectively. Ellis has a success rate of 53% and is ranked #1006 out of 4288 analysts, while Archila has a success rate of 50% and is ranked #2892.

Overall, 5 research analysts have assigned a Hold rating and 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $28.67 which is 78.9% above where the stock closed yesterday.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets.